Äèñêóññèîííûé Êëóá

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Àêóøåðñòâî è ãèíåêîëîãèÿ > Ïðåðûâàíèå áåðåìåííîñòè (àáîðò, âûêèäûø, íåðàçâèâàþùàÿñÿ áåðåìåííîñòü)

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #16  
Ñòàðûé 12.01.2005, 18:58
Tess_a Tess_a âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 06.01.2005
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 17
Tess_a *
Öèòàòà:
Ñîîáùåíèå îò Chebotnikova T.
... íè ïðè êàêîì çàáîëåâàíèè (äàæå ïðè ðîäèëüíîé ãîðÿ÷êå) íå íóæíû îäíîâðåìåííî 12 ãîðìîíàëüíûõ ïîêàçàòåëåé.
Tess_a, ÷òî Âû äåëàåòå?
..ýòî íå ÿ, ýòî ìíå âðà÷ íàçíà÷èëà âñå ýòè ïðîöåäóðû..
ß âîò ïîòîìó è èíòåðåñîâàëàñü, òàêèì ëè äîëæåí áûòü ïëàí îáñëåäîâàíèÿ ïðè íåðàçâèâàþùåéñÿ áåðåìåííîñòè?!

À ÷òî, ïî âàøåìó ìíåíèþ, íóæíî áóäåò ñäåëàòü äëÿ âûÿâëåíèÿ ïðè÷èí(û) íåðàçâ.áåð.??
Îòâåòèòü ñ öèòèðîâàíèåì
  #17  
Ñòàðûé 12.01.2005, 19:19
Chebotnikova T. Chebotnikova T. âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 30.08.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,008
Ñêàçàë(à) ñïàñèáî: 4
Ïîáëàãîäàðèëè 249 ðàç(à) çà 244 ñîîáùåíèé
Chebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Tess_a,

ïàðàäîêñ çàêëþ÷àåòñÿ â òîì, ÷òî áûâøàÿ îäíàæäû íåðàçâèâàþùàÿñÿ áåðåìåííîñòü íå ÿâëÿåòñÿ ïîêàçàíèåì äëÿ äîïîëíèòåëüíîãî îáñëåäîâàíèÿ (ÿ ïîíèìàþ, ÷òî Âàì íåïðîñòî îñîçíàòü òàêîé ôàêò, íî...)

òî åñòü ôàêòè÷åñêè âðà÷, ðåêîìåíäóÿ äîïîëíèòåëüíûå èññëåäîâàíèÿ, èäåò ó Âàñ íà ïîâîäó, æåëàÿ Âàñ óñïîêîèòü è ïðèäàòü Âàì óâåðåííîñòè. Èç âñåãî ñïèñêà äîñòóïíûõ èññëåäîâàíèé ìîæíî âûáðàòü òîëüêî òå, êîòîðûå ìîãóò äåéñòâèòåëüíî ïîìî÷ü (ìàðêåðû ÀÔÑ, íàïðèìåð, ) èç âñåãî ñïèñêà ãîðìîíàëüíûõ èññëåäîâàíèé - ÒÒÃ, èç èíôåêöèé - â ïåðâóþ î÷åðåäü ÀÒ ê ÖÌÂ.

Âàì áûë ââåäåí àíòèðåçóñ-ãàììàãëîáóëèí ïîñëå ïðåðûâàíèÿ áåðåìåííîñòè (îáà ðàçà)?
Îòâåòèòü ñ öèòèðîâàíèåì
  #18  
Ñòàðûé 13.01.2005, 11:30
Tess_a Tess_a âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 06.01.2005
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 17
Tess_a *
Öèòàòà:
Ñîîáùåíèå îò Chebotnikova T.
Tess_a,

Âàì áûë ââåäåí àíòèðåçóñ-ãàììàãëîáóëèí ïîñëå ïðåðûâàíèÿ áåðåìåííîñòè (îáà ðàçà)?
ß, ÷åñòíî ãîâîðÿ, äàæå íå çíàëà î òîì, ÷òî îáÿçàòåëüíî íóæíî ââîäèòü ýòîò ïðåïàðàò. Ïîýòîìó ÿ íå èíòåðåñîâàëàñü òîãäà, â 1999 ã. î òîì, ââåëè ëè ìíå åãî èëè íåò. ß ïîëàãàþ, ÷òî äà, èíà÷å áû ó ìåíÿ ïðè ñëåä áåð. îáíàðóæèëè ðåçóñ-àíòèòåëà, òàê âåäü?

À ÷òî êàñàåòñÿ íåð.áåð., òî â áîëüíèöå, ãäå ìíå äåëàëè âûñêàáëèâàíèå, íàâåðíÿêà äîëæíû áûëè åãî ââåñòè, âåäü ó íèõ áûëè âñå ìîè àíàëèçû. Ïîïûòàþñü óòî÷íèòü ó âðà÷à.

À ïî ïîâîäó íàçíà÷åíèÿ âðà÷îì ñäà÷ó êðîâè íà ãîðìîíû, òî ìîåé èíèöèàòèâû çäåñü íåò, íî ÿ õî÷ó äåéñòâèòåëüíî ïîñìîòðåòü íà ðåçóëüòàòû, à âäðóã ýòî èç-çà íèõ (ïðåäïîëîæèì, ÷òî ÀÔÑ íå ïðè ÷åì). Ïðîñòî ÷òîáû â ñëåä . ðàç áûòü óâåðåííîé íà 100%, îò ÷åãî ìîæåò ÷òî-òî ñëó÷èòñÿ, à ÷òî íèêàê íå ïîâëèÿåò.

_________________________
Ñ óâàæåíèåì,
Tess_a.
Îòâåòèòü ñ öèòèðîâàíèåì
  #19  
Ñòàðûé 13.01.2005, 17:18
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,756
Ïîáëàãîäàðèëè 33,414 ðàç(à) çà 31,759 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ äîêòîð ×åáîòíèêîâà Ò.!

Âàì íå êàæåòñÿ, ÷òî äàííûå ïåðâîãî ñîîáùåíèÿ Tess_a
" ôåâðàëå 2004 óçíàëà î ñâîåé áåðåìåííîñòè (âòîðàÿ)...Ïåðâàÿ áåðåìåííîñòü çàêîí÷èëàñü â 1999 ãîäó àáîðòîì íà 8 íåäåëå"
íå ñîâñåì óêëàäûâàþòñÿ â îïðåäåëåíèå "áûâøàÿ îäíàæäû íåðàçâèâàþùàÿñÿ áåðåìåííîñòü"?

Ñîïîñòàâèìû ëè ïåðâè÷íûå äàííûå " 1999 ã. âåñíîé áûëà ïëåâðàëüíàÿ ïíåâìîíèÿ, âûçâàííàÿ òðîìáîçîì ëåãî÷íîé àðòåðèè.  2001 ã. âåñíîé áûë òðîìáîç íèæíåé ïîäâçäîøíîé âåíû íà ëåâîé íîãå," ñ ìåæäóíàðîäíûìè ðåêîìåíäàöèÿìè èëè íåò?

In patients with multiple (two or more) episodes of VTE and/or women receiving long-term anticoagulants (eg, single episode of VTE—either idiopathic or associated with thrombophilia) we suggest adjusted-dose UFH or adjusted-dose LMWH followed by resumption of long-term anticoagulants postpartum (Grade 2C).

...women with recurrent pregnancy loss, a second trimester miscarriage, or a history of intrauterine death or severe or recurrent preeclampsia should be screened for underlying congenital thrombophilias. ... since many of these women also have an increased risk of VTE, antithrombotic therapy should be considered in this population.

Èç Use of Antithrombotic Agents During Pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Shannon M. Bates, Ian A. Greer, Jack Hirsh, and Jeffrey S. Ginsberg
Chest 126: 627S-644S.

Ïðèìåðíî òî æå èç Åâðîïû:

Patients who have hereditary antithrombin deficiency, antiphospholipid antibodies, a combined abnormality, or a history of a severe thrombotic event (pulmonary embolism or extended deep vein thrombosis) should be advised to use prophylactic heparin during pregnancy, starting during the first trimester. Postpartum prophylaxis should be given to all women with an increased risk for VTE.

Pabinger I, Grafenhofer H.Anticoagulation during pregnancy.
Department of Hematology and Blood Coagulation, University Clinic I, University Hospital Vienna, Vienna, Austria. Èç Semin Thromb Hemost. 2003 Dec;29(6):633-8.
Îòâåòèòü ñ öèòèðîâàíèåì
  #20  
Ñòàðûé 13.01.2005, 18:08
Chebotnikova T. Chebotnikova T. âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 30.08.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,008
Ñêàçàë(à) ñïàñèáî: 4
Ïîáëàãîäàðèëè 249 ðàç(à) çà 244 ñîîáùåíèé
Chebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé äîêòîð Âàäèì!

 ñîîáùåíèè Tess_a ðå÷ü èäåò î ïåðâîé áåðåìåííîñòè, ïðåðâàííîé ïî æåëàíèþ æåíùèíû, ò.å. î ìåäèöèíñêîì ïðåðûâàíèè áåðåìåííîñòè (àáîðòå) â ðåçóëüòàòå ðåøåíèÿ æåíùèíû.

Öèòàòà:
Ñîîáùåíèå îò Tess_a

Ïåðâàÿ áåðåìåííîñòü çàêîí÷èëàñü â 1999 ãîäó àáîðòîì íà 8 íåäåëå (âðà÷ íà Óçè ãîâîðèëà, ÷òî ðåáåíîê ðàçâèâàëñÿ íîðìàëüíî, ñîîòâåòñòâåíî ñðîêó, çäîðîâûé)!
 ôåâðàëå 2004 óçíàëà î ñâîåé áåðåìåííîñòè (âòîðàÿ). Âðà÷ íàçíà÷èëà ïîâòîðíîå ÓÇÈ ÷åðåç íåäåëþ, è ïî åãî ðåçóëüòàòàì áûëî ñäåëàíî çàêëþ÷åíèå î ãèáåëè ïëîäà íà 5 íåäåëå (õîòÿ ðåàëüíûé ñðîê äîëæåí áûë áûòü îêîëî10 íåäåëü).
À âîò âòîðàÿ áåðåìåííîñòü áûëà íåðàçâèâàþùåéñÿ.

Òî, ÷òî äîïîëíèòåëüíî ñîîáùèëà î ñåáå Tess_a, äàåò íàì ñ Âàìè âñå îñíîâàíèÿ èññëåäîâàòü ìàðêåðû òðîìáîôèëèè, íåçàâèñèìî îò íàëè÷èÿ çàìåðøåé áåðåìåííîñòè â àíàìíåçå.

Î ÷åì ìû ñ Âàìè ñîáèðàåìñÿ äèñêóòèðîâàòü?
Îòâåòèòü ñ öèòèðîâàíèåì
  #21  
Ñòàðûé 13.01.2005, 18:25
Chebotnikova T. Chebotnikova T. âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 30.08.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,008
Ñêàçàë(à) ñïàñèáî: 4
Ïîáëàãîäàðèëè 249 ðàç(à) çà 244 ñîîáùåíèé
Chebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Tess_a ,

êàæäàÿ áåðåìåííîñòü Rh-îòðèöàòåëüíîé æåíùèíû ïëîäîì, èìåþùèì +Rh-ôàêòîð óâåëè÷èâàåò øàíñ ïîÿâëåíèÿ àíòèòåë ê Rh-ôàêòîðó (Rh-êîíôëèêò) â ñðåäíåì íà 10%. È íå òàê âàæíî, áûëè ðîäû èëè áåðåìåííîñòü çàêîí÷èëàñü àáîðòîì. Ôàêò íàëè÷èÿ àíòèòåë - ýòî íå áîëåçíü, ýòî òîëüêî ïîâûøàåò ðèñê ðàçâèòèÿ ãåìîëèòè÷åñêîé áîëåçíè ïëîäà. Äðóãèìè ñëîâàìè, àíòèòåëà Rh-ôàêòîðó ê åñòü ó ìíîãèõ áåðåìåííûõ ñ Rh-, íî øàíñ èìåòü òÿæåëîå ïîâðåæäåíèå òêàíåé ïëîäà (ãåìîëèòè÷åñêóþ áîëåçíü ïëîäà) â ïðèíöèïå î÷åíü ìàë. Òàêèõ áåðåìåííûõ åäèíèöû! ß óæå íå ðàç ïèñàëà îá ýòîì íà ôîðóìå â äðóãèõ äèñêóññèÿõ. Òî åñòü Rh-êîíôëèêò (íàëè÷èå àíòèòåë) ýòî íå ïðèãîâîð, à òîëüêî ïîâîä óäåëèòü Âàì äîïîëíèòåëüíîå âíèìàíèå âî âðåìÿ ñëåäóþùåé áåðåìåííîñòè.

Äëÿ òîãî, ÷òîáû ñíèçèòü ðèñê èììóíèçàöèè ó Rh-îòðèöàòåëüíîé æåíùèíû, íå èìåþùåé àíòèRh-àíòèòåë, ïîñëå ðîäîâ èëè àáîðòà ââîäÿò àíòèðåçóñ ãàììàãëîáóëèí.
Îòâåòèòü ñ öèòèðîâàíèåì
  #22  
Ñòàðûé 13.01.2005, 18:30
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,756
Ïîáëàãîäàðèëè 33,414 ðàç(à) çà 31,759 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìàÿ Äîêòîð Òàòüÿíà!

Êîãäà ïàöèåíòêè ïèøóò "... çàêîí÷èëàñü àáîðòîì", ýòî ðàçâå íå ñàìîïðîèçâîëüíûé? Ìíå ïîêàçàëîñü èìåííî ýòî. Îáû÷íî ãîâîðÿò, ÷òî "ïðåðâàëà áåðåìåííîñòü, ñäåëàëà àáîðò". Ïóñòü íàñ ðàññóäèò Tess_a.

Âû æå ïðåêðàñíî çíàåòå, ñêîëüêî ìîæåò ñòîèòü âñÿ òðîìáîôèëè÷åñêàÿ ïàíåëü èññëåäîâàíèÿ è äåëàþò ëè åå äàæå â Ìîñêâå â ïîëíîì îáüåìå. Òåì áîëåå, ÷òî ïðèðîäà ïîëîâèíû èç òðîìáîôèëèé ïîêà íå óñòàíîâëåíà è èäåò ïîä ìàðêîé "èäèîïàòè÷åñêèé òðîìáîç".

Ìíå õî÷åòñÿ âñå æå äîíåñòè ìûñëü, ÷òî âíå çàâèñèìîñòè îò èññëåäîâàíèé íà ïðåäìåò íåâûíàøèâàíèÿ, ïàöèåíòêå ðåêîìåíäóþòñÿ äëÿ ïðîôèëàêòèêè òðîìáîçà àäåêâàòíûå ìåðîïðèÿòèÿ óæå ñîãëàñíî èìåþùåìóñÿ àíàìíåçó, è ñóùåñòâóåò âûñîêàÿ âåðîÿòíîñòü, ÷òî ãåïàðèí ìîæåò ïîâûñèòü øàíñû äîíîñèòü ðåáåíêà. Ñóùåñòâóåò ëè îïûò ó êîãî â Ìîñêâå ïî âåäåíèþ òàêèõ ïàöèåíòîê?
Îòâåòèòü ñ öèòèðîâàíèåì
  #23  
Ñòàðûé 13.01.2005, 18:53
Chebotnikova T. Chebotnikova T. âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 30.08.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,008
Ñêàçàë(à) ñïàñèáî: 4
Ïîáëàãîäàðèëè 249 ðàç(à) çà 244 ñîîáùåíèé
Chebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ß áû ñêàçàëà òàê, - æåíùèíà íèêîãäà íå ïðîìîë÷èò (ñêîðåå ñàìà îáðàòèò Âàøå âíèìàíèå ) íà ôàêò ñàìîïðîèçâîëüíîãî àáîðòà.

Ïî ïîâîäó èíôîðìàòèâíûõ è äîñòóïíûõ äëÿ èññëåäîâàíèÿ ìàðêåðîâ òðîìáîôèëèè, - ÿ áû ëè÷íî õîòåëà çíàòü, ÷òî êðîìå ÂÀ (êàðäèîëèïèíà), è êîñâåííî À×Ò ìîæåò áûòü èíôîðìàòèâíî äëÿ îöåíêè ðèñêà òðîìáîçà, äî íàñòóïëåíèÿ ñîáûòèÿ.

Èäåÿ î ïðîôèëàêòèêå òðîìáîçà õîðîøà áóêâàëüíî âñåì, ÿ ïðåêðàñíî ïîíèìàþ è ïîääåðæèâàþ Âàøè èäåè î ïåðñïåêòèâàõ è àíòèêîàãóëÿíòàõ â öåëîì è òåì áîëåå ïðè ñëåäóþùèõ áåðåìåííîñòÿõ Tess_a. â Ìîñêâå åñòü íåñêîëüêî öåíòðîâ, ðàçðàáàòûâàþùèõ òåìó òðîìáîôèëèè.
Îòâåòèòü ñ öèòèðîâàíèåì
  #24  
Ñòàðûé 13.01.2005, 19:08
Rodionov Rodionov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 28.02.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 9,764
Ïîáëàãîäàðèëè 804 ðàç(à) çà 733 ñîîáùåíèé
Rodionov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåRodionov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåRodionov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåRodionov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåRodionov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåRodionov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåRodionov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåRodionov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåRodionov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåRodionov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåRodionov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Dr. Vad
Êîãäà ïàöèåíòêè ïèøóò "... çàêîí÷èëàñü àáîðòîì", ýòî ðàçâå íå ñàìîïðîèçâîëüíûé? Ìíå ïîêàçàëîñü èìåííî ýòî. Îáû÷íî ãîâîðÿò, ÷òî "ïðåðâàëà áåðåìåííîñòü, ñäåëàëà àáîðò".
Óâàæàåìûé Âàäèì Âàëåðüåâè÷! ß æå ñ ñàìîãî íà÷àëà âûÿñíÿë ýòîò âîïðîñ:
Öèòàòà:
Ñîîáùåíèå îò rodionov
Àáîðò ïî ìåäèöèíñêèì ïîêàçàíèÿì? èëè.. ïî ñîöèàëüíûì?
Îòâåò:
..ïî ñîöèàëüíûì....
Îòâåòèòü ñ öèòèðîâàíèåì
  #25  
Ñòàðûé 13.01.2005, 19:15
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,756
Ïîáëàãîäàðèëè 33,414 ðàç(à) çà 31,759 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
óâàæàåìàÿ äîêòîð Òàòüÿíà!

Êðîìå ïåðå÷èñëåííîãî â òàáëèöå (Kujovich JL.Thrombophilia and pregnancy complications. Am J Obstet Gynecol. 2004 Aug;191(2):412-24), åùå âûäåëÿþò ïîâûøåííóþ êîíöåíòðàöèþ ôàêòîðà VIII (áîëåå 150%):

Marietta M, Facchinetti F, Sgarbi L, Simoni L, Bertesi M, Torelli G, Volpe A. Elevated plasma levels of factor VIII in women with early recurrent miscarriage. J Thromb Haemost. 2003 Dec;1(12):2536-9.

Dossenbach-Glaninger A, van Trotsenburg M, Krugluger W, Dossenbach MR, Oberkanins C, Huber J, Hopmeier P. Elevated coagulation factor VIII and the risk for recurrent early pregnancy loss. Thromb Haemost. 2004 Apr;91(4):694-9.
Èçîáðàæåíèÿ
Òèï ôàéëà: gif TphPL.gif (15.1 Êá, 108 ïðîñìîòðîâ)
Îòâåòèòü ñ öèòèðîâàíèåì
  #26  
Ñòàðûé 13.01.2005, 19:21
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,756
Ïîáëàãîäàðèëè 33,414 ðàç(à) çà 31,759 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Àíòîí Âëàäèìèðîâè÷!

Ñïàñèáî çà ðåìàðêó: äåéñòâèòåëüíî óïóñòèë èç âèäà.

Óâàæàåìàÿ äîêòîð Òàòüÿíà!

Ïðèíîøó ñâîè èçâèíåíèÿ ïî ïîâîäó íåîáîñíîâàííûõ çàìå÷àíèé, ïðîçâó÷àâøèõ â ïåðâîé ÷àñòè ñîîáùåíèÿ #19.
Îòâåòèòü ñ öèòèðîâàíèåì
  #27  
Ñòàðûé 13.01.2005, 22:49
Chebotnikova T. Chebotnikova T. âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 30.08.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,008
Ñêàçàë(à) ñïàñèáî: 4
Ïîáëàãîäàðèëè 249 ðàç(à) çà 244 ñîîáùåíèé
Chebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûå Âàäèì Âàëåðüåâè÷ è Àíòîí Âëàäèìèðîâè÷,

Âàøå ó÷àñòèå â âîïðîñàõ ýòîé ïàöèåíòêè äåëàåò åãî ïîòðÿñàþùå èíòåðåñíûì, - êîãäà áû ìû â ðåàëå ìîãëè ñîáðàòüñÿ äëÿ îáñóæäåíèÿ?
Áûëî áû âîîáùå çàìå÷àòåëüíî, åñëè áû ìàðêåðû òðîìáîôèëèè áûëè äîñòóïíû ïîëüçîâàòåëÿì... À ïîêà âíå íàó÷íûõ èññëåäîâàíèé ó íàñ - À×ÒÂ, Àò-ÊË, ÂÀ. ×òî åùå?

Âàäèì Âàëåðüåâè÷ , çà ññûëêó Âàì îòäåëüíîå ñïàñèáî - ó ìåíÿ ñåé÷àñ ïðîñòî ïîäðÿä íåñêîëüêî ïàöèåíòîê ñ ÀÔÑ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #28  
Ñòàðûé 14.01.2005, 13:02
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,756
Ïîáëàãîäàðèëè 33,414 ðàç(à) çà 31,759 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Thumbs up

Óâàæàåìàÿ Äîêòîð Òàòüÿíà!

äëÿ íà÷àëà ôðàãìåíò, ÷òî ñ÷èòàåòñÿ ãåìîñòàòè÷åñêîé íîðìîé ïðè áåðåìåííîñòè (âûäåëåíî ìíîé, êàê íàèáîëåå ïðèìåíèìîå íà íàøåé òåððèòîðèè):

During normal pregnancy the hemostatic balance changes in the direction of hypercoagulability, thus decreasing bleeding complications in connection with delivery. The most important initial factor for acute hemostasis at delivery is, however, uterine muscle contractions, which interrupt blood flow. Global tests such as Sonoclot signature, the Thromboelastogram, and a new method analyzing overall plasma hemostasis, all show changes representative of hypercoagulability during pregnancy. Increased endogenous thrombin generation, acquired activated protein C resistance, slightly decreased activated partial thromboplastin time (aPTT) and increased prothrombin complex level (PT) measured as international normalized ratio (INR) of less than 0.9 (ïðèìåðíî ñîîòâåòñòâóåò íàøèì çíà÷åíèÿì ÏÒÈ 105-115%) have been reported as well. In normal pregnancy, the platelet count is within normal range except during the third trimester when benign gestational thrombocytopenia, 80 to 150 x 10 9/L, can be observed. Platelet turnover is usually normal. Activation of platelets and release of beta-thromboglobulin and platelet factor 4 are reported. The bleeding time is unchanged during normal pregnancy. Most blood coagulation factors and fibrinogen increase during pregnancy. Factor (F) XI is the only blood coagulation factor that decreases. Blood coagulation inhibitors are mainly unchanged but the level of free protein S decreases markedly and the level of tissue factor pathway inhibitor increases. Thrombomodulin levels increase during pregnancy. Fibrinolytic capacity is diminished during pregnancy, mainly because of markedly increased levels of plasminogen activator inhibitor-1 (PAI-1) from endothelial cells and plasminogen activator inhibitor-2 (PAI-2) from the placenta. Thrombin-activated fibrinolysis inhibitor is reported to be unaffected. The total hemostatic balance has been studied by analyses of prothrombin fragment 1+2, thrombin-antithrombin complex, fibrinopeptide A, soluble fibrin, D-dimer, and plasmin-antiplasmin complex. There is activation of blood coagulation and a simultaneous increase in fibrinolysis without signs of organ dysfunction during normal pregnancy. These changes increase as pregnancy progresses.

Èç Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125-30.
Îòâåòèòü ñ öèòèðîâàíèåì
  #29  
Ñòàðûé 14.01.2005, 13:26
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,756
Ïîáëàãîäàðèëè 33,414 ðàç(à) çà 31,759 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñóùåñòâóåò ýâèäåíñ, ÷òî íèçêèå çíà÷åíèÿ (óêîðî÷åííîå) À×ÒÂ, íî íå ÏÒÈ èëè ôèáðèíîãåí, äî áåðåìåííîñòè ìîãóò ïðåäñêàçûâàòü ïîñëåäóþùåå íåâûíàøèâàíèå:

A shortened aPTT before conception is associated with further miscarriages in patients with a history of recurrent spontaneous abortions who have no antiphospholipid antibodies.

Ogasawara M, Aoki K, Katano K, Aoyama T, Ozaki Y, Suzumori K. Activated partial thromboplastin time is a predictive parameter for further miscarriages in cases of recurrent fetal loss. Fertil Steril. 1998 Dec;70(6):1081-4.

Ýòî ñîïðîâîæäàëîñü îòñóòñòâèåì ïîâûøåíèÿ ôèáðèíîãåíà ê 7-îé íåäåëå (î÷åâèäíî âñëåäñòâèå åãî ÷àñòè÷íîãî ïîòðåáëåíèÿ - îáðàçîâàíèÿ ýêñòðà-ôèáðèíà â ïëàö.ìèêðîöèðêóëÿöèè).

Òðîìáîýëàñòîãðàììà òàêæå ìîæåò ïîìî÷ü â âûÿâëåíèè íàðóøåíèÿ ãåìîñòàçà ïðè ïðàâèëüíîé èíòåðïðåòàöèè. Íèæå ïðèâåäåí ðèñóíîê è åãî ïàðàìåòðû:
r, ìèí - âðåìÿ ðåàêöèè (êàñêàäà ñâåðòûâàíèÿ êðîâè)
k, ìèí - âðåìÿ îáðàçîâàíèÿ ñãóñòêà (îò ïåðâûõ íèòåé ôèáðèíà äî åãî ñòàáèëèçàöèè)
MA, mm - ìàêñèìàëüíàÿ àìïëèòóäà ñãóñòêà
Lys30, % - ïðîöåíò ëèçèñà ñãóñòêà çà 30 ìèí. ((ÌÀ ìèíóñ àìïëèòóäà â ýòîé òî÷êå)/ÌÀ)õ 100%

Ïðè õð. íåâûíàøèâàíèè îáû÷íî ñíèæàåòñÿ r, óâåëè÷èâàåòñÿ MA, íèçêèé % Lys30

Èç: Rai R, Tuddenham E, Backos M, Jivraj S, El'Gaddal S, Choy S, Cork B, Regan L. Thromboelastography, whole-blood haemostasis and recurrent miscarriage. Hum Reprod. 2003 Dec;18(12):2540-3.
Èçîáðàæåíèÿ
Òèï ôàéëà: gif TEG.gif (11.8 Êá, 96 ïðîñìîòðîâ)
Îòâåòèòü ñ öèòèðîâàíèåì
  #30  
Ñòàðûé 17.01.2005, 02:49
Chebotnikova T. Chebotnikova T. âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 30.08.2004
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,008
Ñêàçàë(à) ñïàñèáî: 4
Ïîáëàãîäàðèëè 249 ðàç(à) çà 244 ñîîáùåíèé
Chebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåChebotnikova T. ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Despite these limitations, a recent study by Khamashta and associates has given clinicians a firm basis upon which to approach therapy. In aPL-antibody-positive patients with vascular thromboses (DVT, PE, stroke, TIA, etc.) the risk of recurrent thrombotic events is sufficiently high to warrant lifetime anticoagulation with warfarin to maintain an INR of 3.0 or greater. Lower levels of anticoagulation or anticoagulation with aspirin is not as effective. In addition to anticoagulation, other risk factors for thromboembolic events, including hypertension, hypercholesterolemia, and smoking, must be aggressively controlled, and the use of certain estrogen-containing medications in females should be discouraged. The role of steroids and immunosuppressive agents in discouraging disease expression is undetermined. Plasmapheresis has been advocated for use in life-threatening situations. The use of hydroxychloroquine sulfate has been suggested, but there are no studies testing the drug's efficacy in APS. Aspirin alone has been advocated for very-small-vessel disease, including tiny-vessel cerebrovascular disease. The treatment of APS in pregnancy has been the most systematically studied and has been addressed in an earlier section. Aspirin and heparin combinations are the current choice of treatment.
Autoimmune thrombocytopenia is common in APS and is steroid-responsive. Coexistent thrombosis and thrombocytopenia present a major therapeutic dilemma in the anticoagulated patient. Lower levels of anticoagulation have been utilized (INR 2.0-3.0) for platelet counts of 50,000-100,000. When platelet counts fall below 50,000, steroids have been recommended. For steroid-resistant thrombocytopenia other modalities have been tried including danazol, dapsone, chloroquine, and splenectomy. IV gammaglobulin may be helpful in temporarily increasing platelet counts prior to surgical procedures.
Thomas P. Greco, 1997

 èòîãå - àíòèêîàãóëÿíòû , â ÷àñòíîñòè âàðôàðèí, âî âðåìÿ áåðåìåííîñòè - àíòèêîàãóëÿíòû áåç âàðèàíòîâ, è æåëàòåëüíî , òî÷íåå íàñòîÿòåëüíî ðåêîìåíäîâàòü îòêàçàòüñÿ îò ïðåïàðàòîâ, ñîäåðæàùèõ ïîëîâûå ñòåðîèäû , â ò.÷. ÎÊ.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 16:59.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.